title: Possible mechanism underlying the efficacy of low dose cyclosporine in autoimmune diseases.
authors.forename: M
authors.initials: M
authors.lastname: Matsushita
authors.forename: N
authors.initials: N
authors.lastname: Takeda-Hirokawa
authors.forename: H
authors.initials: H
authors.lastname: Ogasawara
authors.forename: M
authors.initials: M
authors.lastname: Sugiyama
authors.forename: S
authors.initials: S
authors.lastname: Ando
authors.forename: I
authors.initials: I
authors.lastname: Sekigawa
authors.forename: N
authors.initials: N
authors.lastname: Iida
authors.forename: H
authors.initials: H
authors.lastname: Hashimoto
authors.forename: S
authors.initials: S
authors.lastname: Hirose
mesh_terms: D000328:Adult; D016516:CD4-CD8 Ratio / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use; D016572:Cyclosporine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006684:HLA-DR Antigens / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D019410:Interleukin-16 / Q000097:blood; D008775:Methylprednisolone / Q000627:therapeutic use; D008947:Mixed Connective Tissue Disease / Q000188:drug therapy* / Q000473:pathology
chemical_list: D006684:HLA-DR Antigens; D007166:Immunosuppressive Agents; D019410:Interleukin-16; D016572:Cyclosporine; D003520:Cyclophosphamide; D008775:Methylprednisolone